Postural effects on peritoneal transport and systemic uptake of radiolabeled monoclonal antibodies
- PMID: 9191877
- PMCID: PMC11037637
- DOI: 10.1007/s002620050370
Postural effects on peritoneal transport and systemic uptake of radiolabeled monoclonal antibodies
Abstract
To optimize the regional delivery advantage with i.p. administration of monoclonal antibody (mAb) for radioimmunotherapy, it may be possible to delay the rate and extent of mAb absorption from the peritoneal cavity by simply altering the position of a patient after radioantibody administration. It has been shown that the hydrostatic pressure against the diaphragm plays a major role in the rate of egress of radioantibodies from the peritoneal cavity and that fluid removal from the peritoneal cavity can be altered by posture. The current study examined postural effects in normal rats following the i.p. injection of 125I-5G6.4 murine IgG2a anticarcinoma antibody (45 microCi). A 10-ml injection volume of the radioantibody solution was administered to rats restrained in either a supine or inclined (reverse Trendelenburg; feet down at a 45 degrees angle) position. Pharmacokinetic analysis confirmed that the appearance of the radioantibody into the systemic circulation was delayed in the inclined group. The time to peak blood concentration was prolonged from 14.7 (supine) to 19.2 (inclined) hours (P = 0.005). All other pharmacokinetic parameters were equivalent across the treatment groups. The mean half-life of 166 h, mean blood clearance of 9 ml/min, and mean steady-state volume of distribution of 36 ml were consistent with previous experience with this radioantibody in the rat. The intrinsic absorption profile indicated that the mean percentage absorption from the peritoneal cavity to the blood stream was greater in the supine animals from 4 h after i.p. injection until absorption was complete. By 10 h after injection, absorption from the peritoneal cavity was essentially complete in the supine-dosed animals, while those restrained in an inclined position had cleared only 50% of the total absorbed dose. Hence, the regional delivery advantage afforded by intraperitoneal administration of the radioantibody may be further exploited by maintaining an inclined position throughout the absorption phase, a strategy that may be applicable to radioimmunotherapy of patients.
Similar articles
-
Effect of intraperitoneal injection volume and antibody protein dose on the pharmacokinetics of intraperitoneally administered IgG2a kappa murine monoclonal antibody in the rat.Cancer Res. 1991 Jul 1;51(13):3434-44. Cancer Res. 1991. PMID: 1905196
-
The intraperitoneal delivery of radiolabeled monoclonal antibodies: studies on the regional delivery advantage.Cancer Immunol Immunother. 1988;26(3):187-201. doi: 10.1007/BF00199929. Cancer Immunol Immunother. 1988. PMID: 3383203 Free PMC article.
-
Investigations into the route of uptake and pharmacokinetics of intraperitoneally-administered monoclonal antibodies: I. Transdiaphragmatic blockade of the terminal lymphatics in the rat.Cancer Immunol Immunother. 1990;31(6):365-72. doi: 10.1007/BF01741408. Cancer Immunol Immunother. 1990. PMID: 2386982 Free PMC article.
-
Technology evaluation: CC49 humanized radioimmunoconjugates, National Cancer Institute.Curr Opin Mol Ther. 2003 Aug;5(4):428-32. Curr Opin Mol Ther. 2003. PMID: 14513687 Review.
-
Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer.Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5643s-5645s. doi: 10.1158/1078-0432.CCR-07-0985. Clin Cancer Res. 2007. PMID: 17875801 Review.
Cited by
-
Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis: use relevant to Guillain-Barré syndrome.J Neurosci Res. 2010 Jun;88(8):1651-63. doi: 10.1002/jnr.22330. J Neurosci Res. 2010. PMID: 20077429 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources